Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women

This study has been completed.
Sponsor:
Collaborators:
Canadian Institutes of Health Research (CIHR)
Centre Hospitalier de l'Universite Laval (CHUL)
Information provided by:
Laval University
ClinicalTrials.gov Identifier:
NCT00136643
First received: August 26, 2005
Last updated: October 9, 2007
Last verified: October 2007

August 26, 2005
October 9, 2007
June 2005
Not Provided
Safety and tolerance outcomes: Subjective assessment; Objective assessment
  • Safety and tolerance outcomes:
  • - Subjective assessment
  • - Objective assessment
Complete list of historical versions of study NCT00136643 on ClinicalTrials.gov Archive Site
Acceptability assessment
Same as current
Not Provided
Not Provided
 
Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance and Acceptability of a Vaginal Gel Containing Sodium Lauryl Sulfate (Invisible Condom®) in Healthy Female Subjects

The objectives of this clinical study are to evaluate the extended safety, tolerance and acceptability of a vaginal gel formulation when applied in 452 healthy women volunteers. This vaginal formulation was shown to be well tolerated in a previous smaller clinical study. The formulation is being developed as a microbicide for the prevention of sexually transmitted infections (STIs) including HIV.

Objectives: The objectives of this Phase I/II clinical trial are to evaluate the safety, tolerance and acceptability of a gel formulation containing sodium lauryl sulfate (SLS) (compared to gel alone and placebo) when applied intravaginally in healthy volunteers.

Design: In part A of the protocol, three groups: gel alone, gel plus SLS, and placebo will be tested for safety, tolerance and acceptability when applied intravaginally once, twice or three times daily for 14 days in 252 healthy subjects. The volunteers will be divided as follow: 36 sexually abstinent healthy subjects (12 per group) will apply the gel, gel plus SLS or the placebo once daily for 14 days; 72 sexually active healthy subjects (24 per group) will apply the gel, gel plus SLS or the placebo once daily for 14 days; 72 sexually active healthy subjects (24 per group) will apply the gel, gel plus SLS or the placebo twice daily for 14 days and 72 sexually active healthy subjects (24 per group) will apply the gel, gel plus SLS or the placebo three times daily for 14 days. The gel will be applied between menses. For the sexually active group, the gel should be applied less than 1 hour before sexual intercourse, if planned. Subjects will have vaginal intercourse a minimum of 4 times in a 2-week period of gel application.

In part B of the protocol, the extended safety of the gel alone, gel plus SLS and placebo will be studied when applied intravaginally twice daily for 8 weeks in sexually active healthy subjects. In this part B (actually represents Phase II of the trial), 80 healthy sexually active subjects for the gel alone group and 80 subjects for the gel + SLS group and 40 subjects for the placebo group, will be studied. The part B involves the participation of a total of 200 subjects. Subjects will have vaginal intercourse a minimum of 4 times in a 2-week period of gel application. The gel will be applied between menses. The gel should be applied less than 1 hour before sexual intercourse, if planned, but no more than twice a day.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
  • HIV Infections
  • Sexually Transmitted Diseases
Drug: Invisible Condom®
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
452
July 2007
Not Provided

Inclusion Criteria:

  • Sign an informed consent
  • Healthy female subjects aged between 18 to 49. Healthy female subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination and laboratory tests.
  • Normal physical and gynecological examinations
  • Normal colposcopic examination
  • Have regular menstrual cycle with 21-40 days between menses
  • HIV-negative subjects and at low risk of acquiring HIV
  • At low risk of getting STIs (i.e. sexually abstinent or having history of protected sexual intercourse or having a stable sexual partner). Sexual intercourse is defined here as vaginal penetration. Stable sexual partner is defined as the same sexual partner for the length of the study.
  • Agreeing to abstain from sexual intercourse from screening to the end of the study (for sexually abstinent subjects).
  • Agreeing to have sexual intercourse a minimum of 4 times for each period of two weeks of gel application (for sexually active subjects)

Exclusion Criteria:

  • Clinically significant abnormal physical and/or gynecological examination
  • Clinically significant abnormal laboratory findings
  • Allergy to applicator material (polyethylene) or to gel polymer (polyoxyethylene-polyoxypropylene) or to latex
  • Participation in any investigational study involving drugs, vaccines or microbicides in the last 30 days
  • History of toxic shock syndrome
  • HIV infection
  • Bacterial vaginosis or Candida or Trichomonas vaginitis at time of screening
  • STIs (gonorrhea, chlamydia, syphilis, genital herpes, chancroid) at time of screening
  • Breakthrough menstrual bleeding, or vaginal bleeding during or following sexual intercourse, in the last 3 months
  • Intravenous (IV) drug use except for medical reasons in the last year
  • Pregnant at enrolment or breast-feeding
  • Having received antibiotics in the last 14 days
  • Subjects considered as unreliable or unable to understand or follow the study protocol directions
  • Use of an intrauterine device
Female
18 Years to 49 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Cameroon
 
NCT00136643
CRI-INV.06, FRN: 67531
Not Provided
Not Provided
Laval University
  • Canadian Institutes of Health Research (CIHR)
  • Centre Hospitalier de l'Universite Laval (CHUL)
Principal Investigator: Michel G. Bergeron, MD, FRCPC Prof. and Director of Infectious Diseases Research Center, Laval University
Laval University
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP